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1.	INTRODUCTION	
	
	Amyotrophic	lateral	sclerosis	(ALS)	is	a	progressive	neurodegenerative	disease	which	leads	to	muscle	weakness,	atrophy,	spasticity	and	eventually	death	from	respiratory	failure,	usually	within	3–5	years	from	symptom	onset.	According	to	revised	El	Escorial	criteria,	ALS	requires	1)	evidence	of	lower	motor	neuron	(LMN)	degeneration	by	clinical,	electrophysiological	or	neuropathological	examination,	2)	evidence	of	upper	motor	neuron	(UMN)	degeneration	by	clinical	examination,	3)	progressive	spread	of	symptoms	or	signs	within	anatomical	regions	or	to	other	regions,	and	4)	no	evidence	of	other	disease	processes	that	might	explain	these	symptoms	and	signs	(1,	2).	By	its	very	definition,	ALS	is	thought	to	affect	mostly	the	lower	and	upper	motor	neurons.	However,	it	is	also	related	to	cognitive	impairment	in	up	to	50%	and	frontotemporal	dementia	(FTD)	in	13.8%	of	patients	(3,	4).		Similarly,	a	subset	of	FTD	patients	presents	with	motor	neuron	symptoms,	and	FTD	and	ALS	are	emerging	as	different	manifestations	of	the	same	disease	spectrum	(5–10).		
1.1	Genetic	background	of	ALS		Most	cases	of	ALS	are	sporadic	(SALS),	but	a	minority	are	familial	(FALS)	with	both	autosomal	dominant	and	recessive	inheritance	patterns.	The	rate	of	FALS	has	been	estimated	at	around	5–10	%,	but	the	true	rate	is	most	likely	higher	and	even	as	high	as	16–20%	(11–13).	Even	in	sporadic	ALS,	twin	studies	suggest	that	heritability	would	explain	61%	of	disease	development	(14).	Sporadic	and	familial	ALS	do	not	differ	in	their	clinical	picture,	and	are	sometimes	hard	to	differentiate	due	to	uncertainty	in	family	history	(15).		Several	genes	have	been	implicated	in	the	pathology	of	ALS.	The	most	common	autosomal	dominant	gene	mutation	is	the	GGGGCC	hexanucleotide	repeat	in	C9orf72,	which	was	discovered	in	2011	(16,	17).	The	other	common	dominant	mutations	include	SOD1,	TARDBP,	and	FUS.		In	Europe,	C9orf72	accounts	for	29.3–38.2%	of	FALS	and	~5%	of	SALS	(18).	
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According	to	a	recent	meta-analysis	by	Zou	et	al	(2017),	C9orf72	is	less	common	in	Asia	than	Europe,	with	a	frequency	of	only	0.3–6.3%	in	FALS.	Interestingly,	the	authors	also	discovered	co-occurrence	of	the	four	most	common	mutations	in	0.4%	in	FALS	cases,	which	implies	at	least	in	part	oligogenic	pathology	for	ALS	(18).	
	
1.2	ALS	in	Finland		In	Finland,	the	frequency	of	C9orf72-related	ALS	is	higher	than	elsewhere,	accounting	for	46.0%	of	FALS	patients	and	as	much	as	21.1%	of	SALS	patients.	In	addition,	SOD-1	mutation	is	particularly	common	in	Finland,	accounting	for	42.9%	of	FALS	and	11.3%	of	SALS.	(15)	Nearly	all	SOD-1	mutations	are	dominantly	inherited,	but	the	most	common	type	in	Finland,	familial	SOD-1	D90A,	has	a	recessive	inheritance	pattern.	The	familial	recessive	SOD-1	D90A	ALS	has	a	markedly	slow	disease	progression	that	usually	starts	from	lower	limbs	with	predominantly	UMN	signs.	The	average	disease	duration	is	over	ten	years	and	many	live	past	two	decades	after	disease	onset.	(19,	20)	The	recessive	D90A	SOD-1	allele	is	found	mostly	in	Scandinavian	countries	and	may	be	tightly	linked	with	a	protective	genetic	factor	(10,	21).				Considering	how	common	both	C9orf72	and	SOD-1	are	in	Finland,	it	is	not	a	surprise	that	the	incidence	of	ALS	in	Finland	has	been	estimated	at	2.4	per	100,000	person-years,	which	is	one	of	the	highest	in	the	world	(22).	There	may	be	more	factors	affecting	the	incidence	rate,	but	the	impact	of	these	two	mutations	in	the	population	is	indisputable.	Together,	C9orf72	and	SOD-1	mutations	account	for	87%	of	FALS	in	Finland	(17).				
1.3	C9orf72-related	ALS	
	C9orf72	mutation	causes	both	ALS	and	FTD.	It	is	not	yet	clear	why	it	presents	as	FTD	in	some	patients	and	ALS,	or	a	combination	of	both,	in	others	(6).	The	exact	pathological	mechanism	is	still	unclear,	but	accumulation	of	nuclear	RNA	foci,	TDP-43	pathology	and	p62-	and	ubiquitin-positive	dipeptide	repeat	protein	inclusions	are	implicated	(8).	While	the	normal	repeat	length	is	between	two	and	ten	units	for	90%	of	the	population,	it	is	still	not	known	how	many	GGGGCC	hexanucleotide	repeats	are	required	to	induce	disease	(23).	Initially,	C9orf72	mutation	was	assumed	fully	penetrant,	but	there	is	now	evidence	of	
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incomplete	penetrance	(24,	25).				The	clinical	characteristics	of	the	C9orf72-mutated	ALS	(C9-ALS)	phenotype	have	been	depicted	in	several	cohort	studies.	C9-ALS	is	correlated	with	an	earlier	age	at	onset	and	shorter	disease	duration	compared	with	non-C9	ALS	(4,	18–22).	Some	studies	have	reported	bulbar	onset	to	be	more	common	with	C9orf72	(20,	23).		Dementia	has	typically	been	present	in	a	much	higher	proportion	of	patients	compared	with	other	ALS	patients,	most	notably	behavioral-variant	FTD	but	also	early-onset	Alzheimer’s	disease	(24,	25).	Of	note	is	also	the	observation	that	a	high	rate	of	psychosis	and	hallucinations,	as	well	as	parkinsonism	have	been	reported	in	association	with	C9orf72	(12,	34).	A	recent	study	found	a	gender	effect,	with	C9-ALS	males	with	spinal	onset	having	significantly	lower	survival	compared	with	other	ALS	patients	with	spinal	onset	(35).	There	is	also	evidence	of	genetic	anticipation,	with	mutation	carriers	in	successive	generations	having	earlier	ages	at	onset	(20,	28).		
1.4	Purpose	of	the	study		At	this	point,	it	is	clear	that	C9-ALS	seems	to	have	high	variability	in	its	phenotype,	and	most	likely	several	factors	modifying	its	disease	risk	and	disease	course.	The	aim	of	this	study	is	to	describe	the	phenotype	of	C9-ALS	in	a	Finnish	cohort	and	report	patient	cases	with	atypical	phenotypes.				
2.	METHODS	
	
	
2.1	Data	collection	
	All	patients	identified	as	C9orf72-positive	at	the	department	of	Neurology	in	Tampere	University	Hospital	before	October	2017	were	included	in	our	study	(n=30).	In	addition,	seven	cases	from	Seinäjoki	Central	Hospital,	three	cases	from	Vaasa	Central	Hospital	and	one	
	 4	
case	from	Turku	University	Hospital	were	included.	All	genetic	investigations	of	the	patients	were	performed	in	Tampere	University	Hospital.		The	medical	records	of	these	patients	were	systematically	reviewed	to	obtain	details	of	disease	phenotype	including	gender,	age	of	onset,	age	at	diagnosis,	disease	onset	type	(spinal,	bulbar,	or	multifocal),	disease	duration,	history	of	memory	or	cognitive	function,	parkinsonism,	psychosis,	upper	motor	neuron	(UMN)	symptoms	and	lower	motor	neuron	(LMN)	symptoms.	Recorded	upper	motor	neuron	symptoms	included	spasticity,	Babinski	reflex,	and	hyperreflexia.	Recorded	lower	motor	neuron	symptoms	included	muscle	atrophy,	fasciculations	and	an	abnormal	electroneuromyography	(ENMG)	finding.	Patients	who	did	not	have	a	diagnosis	of	clinically	definite,	probable	or	possible	ALS	according	to	El	Escorial	revised	criteria	were	left	out	of	the	study	(n=6)	(1,	2).	These	excluded	cases	presented	only	with	symptoms	of	FTD	and	no	significant	motor	neuron	symptoms.	In	addition,	one	case	was	left	out	due	to	insufficient	information.	All	patients	included	in	the	study	had	signed	a	written	form	of	consent.		
2.2	Statistical	analysis	
	Collected	data	was	analysed	using	IBM	SPSS	Statistics	23.0.	Indiscrete	variables	such	as	age	at	onset,	age	at	death	and	disease	duration	were	described	using	median,	mean,	range	and	standard	deviation	and	compared	in	subgroups	based	on	gender,	disease	onset	type,	and	family	history	using	either	2-sample	t-test	or	Mann-Whitney	U-test.	Variances	were	compared	with	Levene’s	test.	Discrete	variables	(rate	of	dementia,	psychosis,	LMN	and	UMN	symptoms)	were	described	using	frequency	tables	and	compared	in	subgroups	of	gender	and	disease	onset	type	with	χ-square	test	or	Fisher’s	exact	test	when	applicable.	A	significance	level	of	<0.05	was	used	for	all	statistical	tests.					
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3.	RESULTS			The	clinical	phenotype	of	37	C9-ALS	patients	was	analysed.	Twenty	of	these	patients	were	male	and	17	female.	By	the	end	of	our	study	period,	eight	patients	were	still	alive	without	tracheostomy,	and	one	patient	with	tracheostomy.	One	patient	had	died	from	myocardial	infarction	and	27	patients	from	ALS.			
3.1	Age	of	onset		The	mean	age	of	onset	was	60.0	years	(SD	9.8	years),	ranging	from	33.3	to	80.8	years.	37.8%	of	patients	had	a	bulbar	or	multifocal	onset	(24.0%	and	13.5%,	respectively).	Spinal	onset	tended	to	have	an	earlier	age	at	onset	than	bulbar	onset	(58.6	versus	62.3	years).	However	the	difference	was	not	statistically	significant	(p=0.25).	There	was	no	difference	in	disease	onset	type	between	sexes.			
	 Number	
of	
patients	
Mean	
age	at	
onset,	
yrs	
Mean	age	
at	
diagnosis,	
yrs	
Median	
disease	
duration,	
yrs	
Median	
disease	
duration,	
deceased,	
yrs	
Mean	
age	at	
death,	
yrs	
FTD,	
number/%	
All	
patients	
37	 60.0	 62.3	 3.3	 3.0	 65.2	 14/37.8	
Male	 20	(54.1%)	 58.8	 61.5	 3.2	 3.2	 63.4	 11/55.0	
Female	 17	(45.9%)	 61.4	 63.2	 3.3	 2.9	 67.8	 3/17.6		
Spinal	
onset	
23		(62.1%)	 58.6	 61.6	 3.7	 3.6	 64.6	 9/39.1	
Bulbar	or	
multifocal	
onset	
13		(37.8%)	 62.3	 63.2	 2.5	 2.1	 65.7	 5/35.7	
Table	1.	Characteristics	of	the	cohort.		
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3.2	Disease	duration		There	was	considerable	variation	in	disease	duration,	which	was	defined	by	the	time	between	symptom	onset	as	reported	by	patients	and	the	end	of	surveillance	(time	of	death	or	tracheostomy,	or	October	2017).	Disease	duration	was	analysed	in	all	patients,	and	separately	including	only	those	who	had	died	from	ALS.	The	range	of	disease	duration	varied	from	10.0	months	to	249.0	months	(20.7	years).		Median	for	disease	duration	was	39.9	months	in	all	patients,	and	35.8	months	in	deceased.	There	was	no	statistically	significant	difference	between	males	and	females.	However,	male	patients	had	more	variance	in	disease	duration	than	female	patients	(p=0.017),	and	this	seemed	to	be	driven	by	higher	variance	in	specifically	spinal-onset	males	compared	with	all	other	patients	(p=0.015)	(See	Fig.	1	and	Table	2).	Bulbar	or	multifocal	onset	group	had	a	significantly	shorter	disease	duration	than	spinal-onset	group,	among	all	patients	(p=0.007)	and	among	the	patients	who	had	died	from	ALS	(p=0.006).	We	also	compared	spinal-onset	males	(n=14)	and	spinal-onset	females	(n=9)	separately,	but	found	no	significant	difference.	More	details	of	the	clinical	characteristics	can	be	seen	in	Tables	1	and	2.	
	
Figure	1.	Disease	duration	(months)	in	male	and	female	patients.	
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	 Mean	
disease	
duration,	
months	
Median	
disease	
duration,	
months	
SD,	months	 Range,	
months	
Difference	
in	disease	
duration	
(Md)	
between	
sexes,	p	
Females	 43.8	 39.6	 20.6	 22.0–110.7	 0.798	
Males	 55.1	 38.6	 55.7	 10.0–249.0	
Spinal-onset	
females	
47.9	 39.9	 25.0	 25.9–110.7	 0.403	
Spinal-onset	
males	
70.5	 59.9	 60.3	 14.7–249.0	
Table	2.	Disease	duration	in	male	and	female	patients	and	spinal-onset	males	and	females.	
	
3.3	Motor	neuron	symptoms		97.3%	of	patients	had	signs	of	lower	motor	neuron	involvement.	All	symptoms	of	lower	motor	neuron	involvement	were	commonly	presented	in	our	patients:	89.2%	had	signs	of	muscle	atrophy,	78.4%	had	fasciculations	and	73.0%	had	ENMG	that	filled	diagnostic	criteria	for	lower	motor	neuron	signs	of	ALS	(2).	There	was	no	significant	difference	between	males	and	females,	or	between	disease	onset	type.	More	details	can	be	seen	in	Table	3a.		91.9%	of	patients	had	signs	of	upper	motor	neuron	involvement.	Hyperreflexia	was	the	most	common	sign	of	upper	motor	neuron	involvement	and	present	in	78.4%	of	patients.	Spasticity	and	an	abnormal	Babinski	reflex	were	less	common,	presenting	in	32.4%	and	24.3%	of	patients,	respectively.	Spasticity	seemed	more	common	in	spinal	onset	(43.5%)	than	in	bulbar	or	multifocal	onset	(14.3%),	but	the	difference	was	not	statistically	significant	(p=0.14).	More	details	can	be	seen	in	Table	3b.				
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	 LMN	
involvement,	
%	
Muscle	
atrophy,	
%	
Fasciculations,	
%	
ENMG	
diagnostic	
(abnormal),	
%	
Muscle	
biopsy	
taken,	
%	
All	 97.3	 89.2	 78.4	 73.0	(83.8)	 32.4		
Male	 100.0	 90.0	 85.0	 80.0	(85.0)	 35.0		
Female	 94.1	 88.2	 70.6		 64.7	(82.3)	 29.4		
Spinal	
onset	
100.0	 95.7	 73.9	 78.3	(91.3)	 39.1	
Bulbar	or	
multifocal	
onset	
92.9	 78.6	 85.7	 64.3	(71.4)	 21.4	
Table	3a.	Lower	motor	neuron	symptoms	in	C9-ALS	patients	
	
	
	
	
	 UMN	
involve-
ment,	%	
Hyper-
reflexia,	
%	
Spasticity,	
%	
Babinski	
positive	
(positive	or	
indifferent)
,	%	
UMN	
excl.	
reflexes1,	
%	
UMN	
excl.	
reflexes2	
,	%	
All	 91.9	 78.4	 32.4	 24.3	(51.3)	 54.1	 40.5	
Male	 90.0	 75.0	 35.0	 25.0	(50.0)	 55.0	 45.0	
Female	 94.1	 82.4	 29.4	 23.5	(52.9)	 52.9	 35.3	
Spinal	
onset	
87.0	 82.6	 43.5	 30.4	(56.5)	 60.9	 52.2	
Bulbar	or	
multifocal	
onset	
100.0	 71.4	 14.3	 14.3	(42.9)	 42.9	 21.4	
Table	3b.	Upper	motor	neuron	symptoms	in	C9-ALS	patients.	1	Rate	of	UMN	pathology,	excluding	hyperreflexia.	2	Rate	of	UMN	pathology,	excluding	hyperreflexia	and	indifferent	Babinski.			
3.4	Dementia,	cognition	and	neuropsychiatric	disorders	
	As	many	as	59.5%	of	patients	had	either	a	diagnosis	of	dementia,	or	their	medical	records	had	noted	issues	with	memory	or	cognitive	decline.	37.8%	had	a	diagnosis	of	FTD	and	5.4%	
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Alzheimer’s	disease.	Three	cases	had	suffered	from	psychosis	at	some	point	in	their	lives,	and	one	case	from	paranoia.	One	patient	had	been	diagnosed	with	parkinsonism.			A	gender	effect	was	observed	regarding	cognitive	symptoms,	with	the	rate	of	FTD	being	significantly	higher	in	male	(55.0%)	than	in	female	patients	(17.6%)	(p=0.02).	When	considering	all	cognitive	decline,	the	rate	in	male	patients	was	also	significantly	higher	than	in	female	patients	(75.0%	versus	41.2%,	p=0.04).	Interestingly	enough,	all	cases	with	psychosis	also	happened	to	be	male	(n=3).	There	was	no	difference	in	memory	symptoms	or	FTD	based	on	disease	onset	type.		
3.5	Family	history	
	75.7%	of	our	patients	had	a	positive	family	history	of	at	least	one	family	member	affected	by	ALS	or	FTD.		Age	at	onset,	disease	duration	and	age	at	the	end	of	surveillance	were	compared	in	subgroups	of	positive	and	negative	or	unknown	family	history,	but	there	were	no	statistically	significant	differences.	However,	the	mean	age	of	onset	for	patients	with	positive	family	history	was	lower	than	that	of	negative	or	unknown	family	history	(58.3	versus	62.7	years),	but	this	was	not	statistically	significant	(p=0.182).		
3.6	Atypical	patient	cases		Three	patients	in	the	cohort	had	unusually	long	survival	with	disease	duration	extending	over	100	months.	All	three	were	spinal-onset.	Two	were	male	and	one	female.				Patient	1	was	a	spinal-onset	male	with	a	positive	family	history	(father	and	father’s	aunt	having	suffered	from	ALS).	Symptoms	started	at	age	34	from	the	left	lower	limb,	and	persisted	in	only	lower	limbs	for	the	first	six–seven	years,	after	which	symptoms	spread	to	the	upper	limbs.	The	patient	expressed	both	UMN	symptoms	(including	spasticity,	hyperreflexia,	and	indifferent	Babinski	sign),	as	well	as	LMN	signs	(muscle	atrophy,	fasciculations,	diagnostic	ENMG).	The	disease	progression	remained	slow	for	over	15	years	before	rapidly	increasing.	The	patient	was	then	restricted	to	a	wheelchair	and	his	speech	began	to	slur.	He	died	from	ALS	at	age	54,	with	an	estimated	disease	duration	of	20.8	years.	
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	Patient	2	was	a	spinal-onset	male	with	no	known	family	history.	His	disease	onset	started	from	upper	limbs	at	age	62.	He	showed	predominantly	LMN	signs,	as	well	as	hyperreflexia	as	the	only	UMN	sign.	His	muscle	atrophy	progressed	very	slowly,	with	disease	duration	125	months	(10.6	years)	at	the	time	of	research.	He	is	still	alive	at	the	time	of	reporting.		Patient	3	was	a	spinal-onset	female	whose	mother	had	an	undiagnosed	motor	neuron	disease.	Her	symptoms	began	at	51	years	as	difficulty	of	walking,	and	remained	isolated	in	just	one	leg	and	later	in	both	lower	limbs.	Later	on,	she	also	developed	mild	signs	of	ALS	in	her	upper	limbs.	Her	symptoms	have	been	UMN-dominant	(spasticity,	hyperreflexia,	positive	Babinski	sign)	with	muscle	atrophy	as	the	only	LMN	sign.	Her	disease	duration	is	110	months	(9.2	years)	at	the	time	of	research	and	she	is	still	alive	at	the	time	of	reporting.		Furthermore,	one	spinal-onset	male	patient	presented	with	a	flail	arm	phenotype,	with	LMN	symptoms	and	hyperreflexia.	He	died	of	traumatic	suffocation	18	months	after	the	onset	of	his	symptoms.	Another	spinal-onset	male	patient	presented	with	spastic	paraplegia	at	the	start	of	his	motor	neuron	disease	with	mostly	UMN	symptoms,	which	later	developed	into	classic	ALS	with	both	LMN	and	UMN	symptoms.	His	disease	duration	was	41	months.			
4.	DISCUSSION			Our	cohort	of	C9orf72-positive	ALS	patients	showed	considerable	heterogeneity	in	their	clinical	presentation.	Age	of	onset	varied	as	much	as	47.5	years	(range	33.3–80.8	years)	and	disease	duration	19.9	years	(range	10.0–248.0	months).	Our	study	population	also	included	a	number	of	cases	with	exceptionally	slow	disease	progression	and	the	clinical	presentation	being	limited	to	just	one	or	two	limbs	for	a	considerable	time,	reminiscent	of	recessive	D90A	SOD1	-linked	ALS	phenotype	(20).	All	of	these	aforementioned	findings	reinforce	that	C9-ALS	can	present	with	any	phenotype	of	ALS.			
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4.1	Disease	onset	and	survival		Studies	have	reported	an	earlier	age	of	onset	and	shorter	survival	for	ALS	in	C9orf72-mutation	carriers	compared	with	non-carriers	(4,	18–22).	Our	study	did	not	have	a	control	group	of	non-carriers,	so	we	cannot	compare	our	findings	regarding	differences	with	non-C9	ALS.	In	relation	to	C9-ALS,	the	mean	age	of	onset	(60.0	years)	was	in	the	same	range	or	slightly	higher	as	in	other	cohort	studies,	where	the	mean	age	of	onset	has	varied	between	54.5–59.3	years	(4,	18–22).		Disease	duration	(median	39.9	months,	range	0.83–20.8	years)	was	somewhat	longer	in	our	cohort	than	in	earlier	reported	studies	(median	20–34.4	months,	range	0.45–13	years)	(6,	27–31).	The	difference	may	be	in	part	due	to	the	limitations	of	a	fairly	small	cohort	size,	but	it	may	also	imply	that	disease	progression	in	C9-ALS	may	be	slightly	slower	in	the	Finnish	population,	possibly	due	to	other	disease-modifying	genetic	or	environmental	factors.		What	was	striking	in	our	cohort	were	the	few	cases	with	extremely	slow	progression	and	long	survival.	Earlier	cohort	studies	have	also	reported	individual	cases	with	exceptionally	long	tracheostomy-free	survival:	in	a	Dutch	cohort	study,	Van	Rheenen	et	al	(2012)	reported	of	one	C9-ALS	patient	with	13	year-survival	and	also	of	one	C9orf72-positive	progressive	muscular	atrophy	(PMA)	patient	with	a	survival	of	21	years,	who	was	still	alive	at	the	end	of	a	study.	Likewise,	Gijselinck	et	al	(2012)	in	a	Flemish-Belgian	cohort	study	reported	of	one	case	with	10-year	survival.	It	is	possible	that	these	cases	with	slow	progression	could	have	a	protective	genetic	factor	(or	factors)	modifying	disease	course.			We	compared	disease	course	of	C9-ALS	in	subgroups	of	patients	based	on	gender	and	disease	onset	type,	as	well	as	family	history.	Bulbar	symptoms	were	found	in	37.8%	of	our	patients	at	disease	onset,	in	keeping	with	reports	of	33–43.5%	bulbar	onset	rate	in	C9-ALS	patients	(26–31).	There	were	no	statistically	significant	differences	in	disease	onset	type,	age	of	onset	or	disease	duration	between	sexes	or	family	history.	Spinal	onset	had	a	significantly	longer	disease	duration	than	bulbar	or	multifocal	onsets,	which	is	a	well-recognised	phenomenon	in	ALS	(37).	Of	interest	is	also	the	fact	that	age	at	onset	was	lower	in	patients	with	a	positive	family	history,	even	though	the	difference	did	not	reach	statistical	significance.	However,	this	trend	would	be	in	keeping	with	findings	of	genetic	anticipation	in	C9-ALS	affecting	age	at	onset	in	successive	generations	(28,	36).	
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	A	recent	study	by	Rooney	et	al	(2017)	combined	data	from	three	separate	ALS	registers	and	found	an	intriguing	gender	effect,	with	C9-ALS	spinal-onset	males	having	shorter	survival	than	other	spinal-onset	ALS	patients.	We	did	not	find	a	difference	in	prognosis	of	spinal-onset	males	compared	with	spinal-onset	females,	although	it	may	have	been	due	to	our	study	population	being	much	smaller.	Interestingly,	we	did	find	that	spinal-onset	males	had	significantly	more	variance	in	disease	duration	than	other	patients,	and	male	patients	more	than	female	patients.	The	difference	between	sexes	seemed	to	be	mostly	driven	by	spinal-onset	males.	This	would	support	the	previously	noted	gender	effect	in	spinal-onset	males	affecting	survival	and	disease	course,	even	though	our	study	did	not	perceive	an	effect	on	survival.	How	exactly	this	gender	effect	affects	disease	course,	and	what	mechanism	is	behind	it,	are	fascinating	topics	that	warrant	further	research.			
4.2	Motor	neuron	symptoms	
	C9-ALS	patients	have	been	found	to	present	with	typical	motor	features	of	ALS,	usually	having	both	UMN	and	LMN	symptoms	(6,	31).	Correspondingly,	our	patients	displayed	a	high	frequency	of	both	UMN	symptoms	(91.9%)	and	LMN	symptoms	(97.3%).	However,	upper	motor	neuron	signs	excluding	hyperreflexia	were	seen	in	only	54.1%	of	patients,	and	similar	rates	were	depicted	in	an	earlier	study	(31).	It	seems	that	upper	motor	neuron	symptoms	apart	from	reflex	pathology	are	difficult	to	discern	in	C9-ALS	patients.		This	feature	should	be	taken	into	account	by	clinicians	in	their	clinical	work	when	suspecting	C9-ALS.	The	reason	behind	this	remains	unclear,	but	one	possibility	is	that	generalized	muscle	atrophy	that	is	prevalent	in	C9-ALS	patients	could	mask	signs	of	upper	motor	neuron	damage.		
4.3	Dementia,	family	history	and	study	limitations		The	frequency	of	FTD	and	cognitive	symptoms	was	much	higher	in	our	cohort	(59.5%)	than	other	studies	with	C9-ALS,	where	the	frequency	has	been	31.8–50%	(26,	28,	29,	31).	Even	though	the	rate	of	FTD	and	cognitive	decline	have	been	reported	higher	in	C9-ALS,	our	result	was	most	likely	affected	by	the	fact	that	C9orf72	gene	test	was	taken	only	when	clinicians	
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asked	for	it	specifically,	instead	of	routinely	testing	all	ALS	patients.	Thus,	a	suspicion	of	C9-ALS	has	most	likely	risen	more	easily	when	motor	neuron	symptoms	were	combined	with	dementia	or	cognitive	decline,	and	resulted	in	our	study	population	having	a	skewed	prevalence	of	memory	symptoms.	In	the	same	vein,	the	very	high	frequency	of	a	positive	family	background	(75.7%)	in	our	cohort	has	most	likely	been	affected	in	a	similar	fashion,	as	the	C9orf72	gene	is	known	for	being	the	most	common	cause	for	familial	ALS.			An	interesting	gender	effect	was	observed	with	FTD	and	cognitive	decline	being	significantly	more	common	in	male	than	female	patients.	We	could	not	find	a	satisfactory	explanation	for	this	finding,	although	not	all	confounding	factors,	such	as	alcohol	use,	have	been	accounted	for.	One	drawback	of	our	study	that	could	affect	this	finding	is	the	fact	that	dementia	and	cognitive	decline	were	not	systematically	reviewed	in	each	patient,	and	thus	some	cases	are	likely	to	have	been	missed.	It	may	be	that	female	patients	with	dementia	or	cognitive	decline	would	be	more	easily	missed	than	males.	Similarly	of	interest	was	the	fact	that	all	cases	with	psychosis	(n=3)	and	parkinsonism	(n=1)	in	our	cohort	happened	to	be	male.		Whether	there	is	a	true	gender	effect	in	the	prevalence	of	dementia	and	other	neuropsychiatric	and	extrapyramidal	symptoms	in	C9-ALS	warrants	further	research.		
4.4	Conclusions		This	study	reinforces	findings	that	C9-ALS	has	large	variety	in	its	phenotype	and	can	present	in	any	clinical	form.	Bulbar	dysfunction	was	found	to	be	relatively	common,	in	keeping	with	previous	studies.	An	earlier	report	of	spinal-onset	males	having	shorter	survival	was	not	seen	in	our	smaller	cohort,	but	spinal-onset	males	did	have	significantly	more	variance	in	their	disease	duration	than	other	patients.	In	addition,	we	found	that	male	patients	had	more	FTD	and	cognitive	decline	than	female	patients,	which	should	be	assessed	systematically	in	future	studies.	Similarly,	further	research	on	the	possibility	of	any	gender	effect	regarding	neuropsychiatric	symptoms	is	needed.		 	
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